- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07943052
Intrauterine Misoprostol in Cesarean Delivery: Effect on Postpartum Hemorrhage
Evaluation of the Efficacy of Intrauterine Misoprostol Administration on Postpartum Hemorrhage in Cesarean Operations
This prospective, randomized, controlled, two-arm study evaluates whether adding intrauterine (uterine cornual) misoprostol 400 mcg to standard oxytocin reduces postpartum blood loss in term women undergoing elective cesarean delivery. Participants are randomized 1:1 to standard oxytocin alone or standard oxytocin plus misoprostol. The primary outcome is the change in hemoglobin and hematocrit from preoperative values to 6, 24 and 48 hours after surgery.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
A total of 142 women (71 per group) will be enrolled. The study group receives standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after placental delivery; the control group receives standard oxytocin only. Hemoglobin and hematocrit are measured before surgery and at 6, 24 and 48 hours afterwards, and participants are seen on postoperative day 10 for late complications and adverse events. The surgical team is not masked; participants are not informed of their allocation. An interim safety analysis is planned after 50 participants.
Studietype
Inschrijving (Geschat)
Fase
- Fase 4
Contacten en locaties
Studiecontact
- Naam: Halil Gümüş, MD
- Telefoonnummer: +90 537 673 47 49
- E-mail: dr.halil.gumusrc@gmail.com
Studie Locaties
-
-
-
Istanbul, Turkije (Türkiye)
- Bagcilar Training and Research Hospital, Department of Obstetrics and Gynecology
-
Contact:
- Halil Gümüş, MD
- Telefoonnummer: +90 537 673 47 49
- E-mail: dr.halil.gumusrc@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18-45 years
- Term pregnancy (37 weeks or more)
- Elective cesarean section planned
- ASA I-II
- Written informed consent signed
Exclusion Criteria:
- History of coagulopathy or active bleeding disorder
- Anticoagulant use
- Hemoglobin < 10 g/dL
- Active thromboembolic disease
- Severe hepatic failure
- BMI > 35 kg/m2
- Type 1 diabetes with diabetic nephropathy
- Chronic hypertension
- Gestational hypertension, preeclampsia, eclampsia or HELLP syndrome
- Placenta previa, placental abruption or placental pathology with high bleeding risk
- Multiple pregnancy
- Uterine anomalies
- Intrauterine fetal death
- Epilepsy (diagnosis or history)
- Active malignancy
- Known hypersensitivity to prostaglandins
- Refusal or withdrawal of consent
- Emergency-indicated cesarean sections (including those planned as elective but performed for fetal distress, uterine rupture or other emergency indications)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Misoprostol plus standard oxytocin
Standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after delivery of the placenta during elective cesarean delivery. |
Misoprostol 400 mcg (2 x 200 mcg tablets), single dose placed in the uterine cornual region after delivery of the placenta, in addition to standard oxytocin. Standard oxytocin administered after delivery of the baby according to routine clinical practice (standard of care in both arms). |
|
Actieve vergelijker: Standard oxytocin
Standard oxytocin only, according to routine clinical practice, during elective cesarean delivery. |
Standard oxytocin administered after delivery of the baby according to routine clinical practice (standard of care in both arms). |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in hemoglobin from preoperative value to postoperative 6, 24 and 48 hours
Tijdsspanne: Preoperative, and 6, 24 and 48 hours after surgery
|
Hemoglobin (g/dL) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups. |
Preoperative, and 6, 24 and 48 hours after surgery
|
|
Change in hematocrit from preoperative value to postoperative 6, 24 and 48 hours
Tijdsspanne: Preoperative, and 6, 24 and 48 hours after surgery
|
Hematocrit (%) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups. |
Preoperative, and 6, 24 and 48 hours after surgery
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Need for blood transfusion
Tijdsspanne: From surgery until hospital discharge, up to 48 hours
|
Proportion of participants requiring blood transfusion after surgery. |
From surgery until hospital discharge, up to 48 hours
|
|
Need for additional uterotonic or hemostatic intervention
Tijdsspanne: During surgery and until hospital discharge, up to 48 hours
|
Proportion of participants requiring additional uterotonic agents or other hemostatic interventions. |
During surgery and until hospital discharge, up to 48 hours
|
|
Late postoperative complications and readmission
Tijdsspanne: Up to postoperative day 10
|
Late complications and hospital readmission assessed at the postoperative day 10 visit. |
Up to postoperative day 10
|
|
Misoprostol-related adverse events
Tijdsspanne: Up to postoperative day 10
|
Adverse events potentially related to misoprostol (e.g., fever, shivering, nausea, vomiting, diarrhea) recorded in both groups. |
Up to postoperative day 10
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Cem Yener, MD, Associate Professor, Bagcilar Training and Research Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Pathologische processen
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Verloskundige arbeidscomplicaties
- Zwangerschap Complicaties
- Bloeding
- Puerperale aandoeningen
- Bloeding van de baarmoeder
- Pathologische aandoeningen, tekenen en symptomen
- Post-partumbloeding
- Hormonen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Peptide hormonen
- Peptiden
- Aminozuren, peptiden en eiwitten
- Vetzuren
- Lipiden
- Biologische factoren
- Prostaglandins, synthetisch
- Prostaglandins
- Eicosanoïden
- Vetzuren, onverzadigd
- Autacoïden
- Ontstekingsmediatoren
- Hypofysehormonen, posterieur
- Hypofysehormonen
- Prostaglandins E, synthetisch
- Oxytocine
- Misoprostol
Andere studie-ID-nummers
- E-66291034-50.04-7274
- 248 (Andere identificatie: Istanbul Medipol University Clinical Research Ethics Committee)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .